vs
DigitalOcean Holdings, Inc.（DOCN）与PHIBRO ANIMAL HEALTH CORP（PAHC）财务数据对比。点击上方公司名可切换其他公司
PHIBRO ANIMAL HEALTH CORP的季度营收约是DigitalOcean Holdings, Inc.的1.5倍（$373.9M vs $242.4M），DigitalOcean Holdings, Inc.净利率更高（10.6% vs 7.3%，领先3.2%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 18.3%），DigitalOcean Holdings, Inc.自由现金流更多（$31.1M vs $8.3M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 14.5%）
DigitalOcean Holdings, Inc.是美国跨国科技企业及云服务提供商，总部位于美国科罗拉多州布鲁姆菲尔德，在全球布局15个数据中心，面向开发者、初创企业及中小微企业提供稳定易用的云基础设施即服务平台，助力各类技术团队高效开展业务。
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
DOCN vs PAHC — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $242.4M | $373.9M |
| 净利润 | $25.7M | $27.5M |
| 毛利率 | 58.7% | 35.5% |
| 营业利润率 | 16.0% | 13.5% |
| 净利率 | 10.6% | 7.3% |
| 营收同比 | 18.3% | 20.9% |
| 净利润同比 | 40.5% | 762.1% |
| 每股收益（稀释后） | $0.23 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $242.4M | $373.9M | ||
| Q3 25 | $229.6M | $363.9M | ||
| Q2 25 | $218.7M | $378.7M | ||
| Q1 25 | $210.7M | $347.8M | ||
| Q4 24 | $204.9M | $309.3M | ||
| Q3 24 | $198.5M | $260.4M | ||
| Q2 24 | $192.5M | $273.2M | ||
| Q1 24 | $184.7M | $263.2M |
| Q4 25 | $25.7M | $27.5M | ||
| Q3 25 | $158.4M | $26.5M | ||
| Q2 25 | $37.0M | $17.2M | ||
| Q1 25 | $38.2M | $20.9M | ||
| Q4 24 | $18.3M | $3.2M | ||
| Q3 24 | $32.9M | $7.0M | ||
| Q2 24 | $19.1M | $752.0K | ||
| Q1 24 | $14.1M | $8.4M |
| Q4 25 | 58.7% | 35.5% | ||
| Q3 25 | 59.6% | 32.9% | ||
| Q2 25 | 59.9% | 29.0% | ||
| Q1 25 | 61.4% | 30.1% | ||
| Q4 24 | 57.1% | 32.9% | ||
| Q3 24 | 60.2% | 32.1% | ||
| Q2 24 | 61.0% | 31.9% | ||
| Q1 24 | 60.7% | 30.2% |
| Q4 25 | 16.0% | 13.5% | ||
| Q3 25 | 19.6% | 14.1% | ||
| Q2 25 | 16.3% | 8.9% | ||
| Q1 25 | 17.9% | 9.6% | ||
| Q4 24 | 15.9% | 8.3% | ||
| Q3 24 | 12.4% | 6.8% | ||
| Q2 24 | 11.6% | 6.7% | ||
| Q1 24 | 6.2% | 7.6% |
| Q4 25 | 10.6% | 7.3% | ||
| Q3 25 | 69.0% | 7.3% | ||
| Q2 25 | 16.9% | 4.5% | ||
| Q1 25 | 18.1% | 6.0% | ||
| Q4 24 | 8.9% | 1.0% | ||
| Q3 24 | 16.6% | 2.7% | ||
| Q2 24 | 9.9% | 0.3% | ||
| Q1 24 | 7.7% | 3.2% |
| Q4 25 | $0.23 | $0.67 | ||
| Q3 25 | $1.51 | $0.65 | ||
| Q2 25 | $0.39 | $0.43 | ||
| Q1 25 | $0.39 | $0.51 | ||
| Q4 24 | $0.21 | $0.08 | ||
| Q3 24 | $0.33 | $0.17 | ||
| Q2 24 | $0.20 | $0.02 | ||
| Q1 24 | $0.15 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $254.5M | $74.5M |
| 总债务越低越好 | $1.3B | $624.2M |
| 股东权益账面价值 | $-28.7M | $332.4M |
| 总资产 | $1.8B | $1.4B |
| 负债/权益比越低杠杆越低 | — | 1.88× |
8季度趋势，按日历期对齐
| Q4 25 | $254.5M | $74.5M | ||
| Q3 25 | $236.6M | $85.3M | ||
| Q2 25 | $387.7M | $77.0M | ||
| Q1 25 | $360.4M | $70.4M | ||
| Q4 24 | $428.4M | $67.1M | ||
| Q3 24 | $439.9M | $89.8M | ||
| Q2 24 | $443.1M | $114.6M | ||
| Q1 24 | $419.1M | $98.7M |
| Q4 25 | $1.3B | $624.2M | ||
| Q3 25 | $1.3B | $628.0M | ||
| Q2 25 | — | $631.7M | ||
| Q1 25 | — | $635.4M | ||
| Q4 24 | $1.5B | $639.1M | ||
| Q3 24 | — | $295.2M | ||
| Q2 24 | — | $312.1M | ||
| Q1 24 | — | — |
| Q4 25 | $-28.7M | $332.4M | ||
| Q3 25 | $-69.6M | $311.7M | ||
| Q2 25 | $-175.2M | $285.7M | ||
| Q1 25 | $-210.7M | $266.0M | ||
| Q4 24 | $-203.0M | $246.8M | ||
| Q3 24 | $-211.7M | $258.5M | ||
| Q2 24 | $-253.8M | $256.6M | ||
| Q1 24 | $-286.1M | $270.1M |
| Q4 25 | $1.8B | $1.4B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.7B | $1.4B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.5B | $966.3M | ||
| Q2 24 | $1.5B | $982.2M | ||
| Q1 24 | $1.5B | $979.0M |
| Q4 25 | — | 1.88× | ||
| Q3 25 | — | 2.01× | ||
| Q2 25 | — | 2.21× | ||
| Q1 25 | — | 2.39× | ||
| Q4 24 | — | 2.59× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.22× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $57.3M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $31.1M | $8.3M |
| 自由现金流率自由现金流/营收 | 12.8% | 2.2% |
| 资本支出强度资本支出/营收 | 10.8% | 3.0% |
| 现金转化率经营现金流/净利润 | 2.23× | 0.70× |
| 过去12个月自由现金流最近4个季度 | $180.5M | $47.3M |
8季度趋势，按日历期对齐
| Q4 25 | $57.3M | $19.4M | ||
| Q3 25 | $95.8M | $9.3M | ||
| Q2 25 | $92.4M | $21.3M | ||
| Q1 25 | $64.1M | $43.2M | ||
| Q4 24 | $71.3M | $3.1M | ||
| Q3 24 | $73.4M | $12.6M | ||
| Q2 24 | $71.3M | $28.4M | ||
| Q1 24 | $66.7M | $11.4M |
| Q4 25 | $31.1M | $8.3M | ||
| Q3 25 | $88.0M | $-4.5M | ||
| Q2 25 | $59.3M | $8.1M | ||
| Q1 25 | $2.1M | $35.4M | ||
| Q4 24 | $26.1M | $-4.7M | ||
| Q3 24 | $16.0M | $3.0M | ||
| Q2 24 | $39.5M | $15.4M | ||
| Q1 24 | $23.0M | $1.7M |
| Q4 25 | 12.8% | 2.2% | ||
| Q3 25 | 38.3% | -1.2% | ||
| Q2 25 | 27.1% | 2.1% | ||
| Q1 25 | 1.0% | 10.2% | ||
| Q4 24 | 12.7% | -1.5% | ||
| Q3 24 | 8.1% | 1.2% | ||
| Q2 24 | 20.5% | 5.6% | ||
| Q1 24 | 12.5% | 0.6% |
| Q4 25 | 10.8% | 3.0% | ||
| Q3 25 | 3.4% | 3.8% | ||
| Q2 25 | 15.2% | 3.5% | ||
| Q1 25 | 29.4% | 2.2% | ||
| Q4 24 | 22.1% | 2.5% | ||
| Q3 24 | 28.9% | 3.7% | ||
| Q2 24 | 16.6% | 4.8% | ||
| Q1 24 | 23.6% | 3.7% |
| Q4 25 | 2.23× | 0.70× | ||
| Q3 25 | 0.60× | 0.35× | ||
| Q2 25 | 2.50× | 1.24× | ||
| Q1 25 | 1.68× | 2.07× | ||
| Q4 24 | 3.91× | 0.97× | ||
| Q3 24 | 2.23× | 1.81× | ||
| Q2 24 | 3.73× | 37.80× | ||
| Q1 24 | 4.72× | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOCN
| Scalers | $84.3M | 35% |
| Scalers Plus | $69.9M | 29% |
| Builders | $64.1M | 26% |
| Learners Testers And Other | $24.1M | 10% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
